Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S
Holding
A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand"s patent as covering a particular method of using a drug.
Judgment
Reversed and remanded, 9-0, in an opinion by Elena Kagan on Apr 17, 2012. Justice Sotomayor filed a concurring opinion.
Merits Briefs for Petitioners
- Brief for Caraco Pharmaceutical Laboratories et al.
- Reply brief for Caraco Pharmaceutical Laboratories et al.
Amicus Briefs Supporting Petitioners
- Brief for the Generic Pharmaceutical Association
- Brief for Rep. Henry A. Waxman
- Brief for the United States of America
- Brief for Mylan Pharmaceuticals Inc.,
- Brief for AARP and U.S. PIRG”
Merits Briefs for the Respondents
Amicus Briefs Supporting the Respondents
- Brief for Allergan, Inc. et al.
- Brief for the Pharmaceutical Research and Manufacturers of America
- Brief for the Washington Legal Foundation
[##CERT-STAGE##]
Recommended Citation: Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, SCOTUSblog, https://www.scotusblog.com/cases/caraco-pharmaceutical-laboratories-ltd-v-novo-nordisk-as/